On June 9, 2022, DxTerity Diagnostics announced the commercial launch of its new IFN-1 Test. Type-1 Interferon (IFN-1) is a key lupus biomarker, a measure of lupus disease severity. IFN-1 status may identify people at risk for more severe disease.

It’s the first commercial test of its kind and is now widely available for clinical use. After a blood sample is drawn and lab results are returned, healthcare providers can then interpret the test results and use the information to help guide more personalized treatment decisions. Talk to your doctor to know whether this test is right for you.

Learn more about other lab tests for lupus.

Read the announcement